Compare Five9 Inc (FIVN) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Cassava Sciences Inc — how do they compare? Five9 Inc trades at $36.44 (market cap $2.63B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Five9 Inc is far larger — about 66.8× Cassava Sciences Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Cassava Sciences Inc for 37 Days on average.
| FIVN | FLNA | |
|---|---|---|
Market Cap | $2.63B | $39.40M |
Volume | 1,864,393 | 759,018 |
Sector | Technology | Health |
52-Week High | $38.65 | $4.64 |
52-Week Low | $13.61 | $0.68 |
Typical Hold Time | 72 Days | 37 Days |
Enterprise Value | $2.78B | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $35.10, up 3.91% with strong technical momentum near recent highs. The company shows accelerating revenue growth, reaching $1.15B in 2025 with improving profitability (net margin 4.94%). Recent quarters have consistently beaten EPS estimates, while AI revenue surged 78% YoY to $39M in Q2 2026. Analyst sentiment remains bullish with 61% buy ratings and a $34 consensus target.
Outlook remains positive driven by AI contact center adoption and subscription growth, though high valuation multiples (P/E 51.7) and insider selling present near-term risks. The stock's technical setup suggests continued upside if it maintains above $34 support, but investors should monitor debt levels and competitive pressures in the CCaaS space.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
